REDX PHARMA PLC

("Redx" or the "Company")

Confirmation of Directorate Change

Alderley Park, UK, 6 September 2023 - Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer confirms, today, the appointment of Dr. Joseph Anderson as a Non-Executive Director on the Board of Directors of the Company (the "Board"), effective immediately. Dr. Anderson will join the Board as a representative of Sofinnova Crossover I SLP ("Sofinnova"), one of the Company's major shareholders.

As previously announced on 3 July 2023, Dr. Anderson's appointment was subject to due diligence and other appointment processes which have now completed.

Dr. Jane Griffiths, Chair of the Board, commented: "We are delighted to welcome Joe to the Board of Directors. Joe brings a wealth of experience from both a business strategist and investor perspective. His impressive track record assisting companies through their growth trajectory will be invaluable as Redx continues to develop into a mature, clinical-stage company."

Additional information

The following additional information is provided in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies:

Dr. Joseph Anderson, aged 64, holds or has previously held the following directorships:

Dr. Anderson holds no shares in the Company.

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) in October 2022, with topline data expected in Q1 2024. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report combination with anti-PD-1 Phase 2 data during 2023.  Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA application at the end of 2023.  

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration. 

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.